EN

Stock code: 002653.SZ

Home

News

Innovation

Pipeline R&D Platforms

Products

Product List Product Topics Pharmacovigilance

Investors

Stock Information Company Announcements Market Data Q&A Investor Hotline

Join Us

Talent Philosophy Careers

About Haisco

About Us Business Presence

Contact Us

GLOBAL

English China

SIFU® (Polyene Phosphatidylcholine Injection)

Polyene Phosphatidylcholine Injection

SIFU® (Polyene Phosphatidylcholine Injection)

Drug Introduction

Sifu® (Polyene Phosphatidylcholine Injection) is currently the only* hepatocyte membrane repair injection in China. It is an exclusive first generic drug of Haisco, approved for marketing in 2005. It is indicated for the treatment of various types of liver diseases, such as hepatitis, chronic hepatitis, liver necrosis, liver cirrhosis, hepatic coma (including prodromal hepatic coma), fatty liver (also seen in diabetic patients), biliary obstruction, poisoning; prevention of gallstone recurrence; treatment before and after surgery, especially hepatobiliary surgery; toxemia of pregnancy (including vomiting), psoriasis, neurodermatitis, and radiation syndrome.

References

[1]Front Pharmacol. 2022 Mar 7;13:806787.

[2]Kong M, Li J, Chen Y. The dosage effect of polyene phosphatidylcholine injection for treating patients with acute drug-induced liver injury: a cohort trial [EB/OL]. International Liver Congress 2026 / European Association for the Study of the Liver (EASL) Congress 2026, Barcelona, Spain, 2026. Poster SAT-071.

[3] Patent application document (Authorization announcement date: November 24, 2010, Certificate number: 702172).

Download prescribing information

SIFU® (Polyene Phosphatidylcholine Injection)

Unique category

Currently the only* hepatocyte membrane repair agent in China, a basic treatment drug for liver injury^[1]

Exclusive and pioneering

Exclusive first generic product, filling the gap in hepatoprotective agents for cell membrane repair in China^[2]

High purity and safety

Patented preparation invention and other patents; higher purity after extraction and purification, containing 95% polyene phosphatidylcholine molecules (cell membrane components), with high safety^[3]

Continuous Research Paper Publications Global Academic Influence

With 20 years of clinical application, it is supported by solid evidence. Three real-world studies (RWS) enrolled over 150,000 patients in total, proving that PPC Injection can markedly ameliorate abnormal liver function in patients with liver injury. One cohort study indicated that the 1860 mg/day PPC group was more effective for DILI, with good tolerability. It is recommended in 33 authoritative guidelines and consensus, incorporated into 10 clinical pathways, and cited in 4 interpretation manuals for clinical pathway therapeutic drugs

Sifu was included in the National Basic Medical Insurance Catalog in 2009, and has been used in over 7000 medical institutions, benefiting nearly 100 million patients.

Continuous Research Paper Publications Global Academic Influence

Continuous Research Paper Publications Global Academic Influence

Frequently Asked Questions

Common Questions and Answers

Sisuo® (Polyene Phosphatidylcholine Injection) Frequently Asked Questions

Q

What is the status of SiFu® (Polyene Phosphatidylcholine Injection) in the treatment of liver damage in China?

A

It is the only liver cell membrane repair injection in China at present, and also a basic treatment drug for liver damage.

Q

Is SiFu® (Polyene Phosphatidylcholine Injection) a exclusive first-in-class drug?

A

It is a unique first-in-class drug that fills the gap in domestic liver protection preparations for cell membrane repair.

Q

In which year was Sifu® (Polyene Phosphatidylcholine Injection) launched?

A

Approved for market release in 2005.

Q

What common diseases can Si Fu® (Polyene Phosphatidylcholine Injection) be used to treat?

A

Various types of liver diseases, such as: hepatitis, chronic hepatitis, liver necrosis, cirrhosis, hepatic coma (including prodromal hepatic coma). Fatty liver (also seen in diabetics). Bile duct obstruction. Toxicity. Prevention of gallstone recurrence. Treatment before and after surgery, especially hepatobiliary surgery. Gestational toxemia, including vomiting. Psoriasis, neurodermatitis, radiation syndrome.

Q

Can SiFu® (Polyene Phosphatidylcholine Injection) be used to treat fatty liver?

A

Yes, it is fully applicable to various types of fatty liver, including those associated with diabetes.

Q

Does Si Fu® (Polyene Phosphatidylcholine Injection) help with gallbladder diseases?

A

Can repair liver and gallbladder cells, improve bile stasis, and promote recovery from conditions such as cholecystitis and gallstones, as well as related surgical injuries.

Q

What is the use of SiFu® (Polyene Phosphatidylcholine Injection) in surgical operations?

A

Used for treatment before and after surgery, especially for hepatobiliary operations. Perioperative hepatobiliary protection to prevent and treat surgical-related liver damage and bile metabolism disorders, and to accelerate the recovery of hepatobiliary functions after surgery.

Q

What other non-gallbladder diseases can Sifu® (Polyene Phosphatidylcholine Injection) be used to treat?

A

It can be used for pregnancy toxemia (including vomiting), psoriasis, neurodermatitis, and radiation syndrome.

Q

What technical advantages does SiFu® (Polyene Phosphatidylcholine Injection) have in terms of purity?

A

The extracted refined product has extremely high purity, with 95% polyene phosphatidylcholine molecules (the core component of cell membranes) in high concentration.

Q

What patents does SiFu® (Polyene Phosphatidylcholine Injection) possess?

A

It has multiple core patents including preparation and invention technologies, and its clinical safety is very high.

Q

As of May 2026, how long has the clinical use experience of Sifu® (doprene phosphatidylcholine injection) been?

A

It has accumulated 20 years of clinical application experience, and evidence-based evidence is sufficient.

Q

As of May 2026, has Si Fu® (dolichol phosphatidylcholine injection) completed several real world studies?

A

Three large-sample real-world studies have been conducted and completed, and 3 SCI papers have been published.

Q

How many cases were included in the RWS study of Sifu® (Polyene Phosphatidylcholine Injection)?

A

Three RWS studies included data from over 150,000 patients using polyene phosphatidylcholine in clinical applications.

Q

What are the conclusions of the real-world study on Sisiu® (Polyene Phosphatidylcholine Injection)?

A

Polyene phosphatidylcholine effectively treats liver damage caused by various factors. Higher doses yield better results and help patients recover more quickly.

Q

As of May 2026, how many guidelines and consensus recommendations has Sifu® (dopren phosphatidylcholine injection) received?

A

A total of 33 authoritative guidelines and consensus recommendations have been obtained.

Q

As of May 2026, how many clinical pathways has Sifu® (dolichol phosphatidylcholine injection) been included in?

A

Has officially adopted the 10 official clinical pathways.

Q

How is Sifu® (Polyene Phosphatidylcholine Injection) included in clinical pathway definitions?

A

It has been included in four volumes of clinical pathway (therapeutic drugs) definitions.

Q

In which year did Si Fu® (Polyene Phosphatidylcholine Injection) enter the medical insurance system?

A

In early 2009, it officially joined the national medical insurance system.

Q

As of May 2026, how many medical institutions has Sifu® (Polyene Phosphatidylcholine Injection) covered?

A

Over 7,000 medical institutions of various types have been established nationwide.

Q

As of May 2026, what is the total number of clinical uses of Sifu® (dolicholphosphatidylcholine injection)?

A

In long-term clinical applications, nearly 100 million patients have benefited so far.